This article is more than 5 years old. Information may no longer be current.
Corticosteroid reduces pain, inflammation after cataract surgery
Loteprednol etabonate gel effectively treated pain and inflammation after cataract surgery, according to a study.
The prospective study included 406 patients with anterior chamber cell grade 2 or higher after cataract surgery; 203 patients were randomized to loteprednol etabonate 0.5% gel and 203 patients were randomized to vehicle four times daily for 14 days.
The final analysis included 199 patients from the loteprednol etabonate group and 198 patients from the vehicle group.
The authors analyzed resolution of anterior chamber cell, pain, adverse events, IOP, visual acuity, biomicroscopy and funduscopy findings, and tolerance to treatment.
Study results showed that anterior chamber cell resolved completely in 30.5% of patients in the loteprednol etabonate group and 16.3% of patients in the vehicle group at 8 days; 72.9% of patients in the loteprednol etabonate group and 41.9% of patients in the vehicle group had pain scores of zero. Both between-group differences were statistically significant (P < .001).
More than 85% of patients in both groups reported no sensation during drop instillation.
IOP increased at least 10 mm Hg in one patient in each group, the authors said.